{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:08:55Z","timestamp":1784182135417,"version":"3.55.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The development of innovative vaccine platforms, including protein subunit and nucleic acid vaccines, has advanced rapidly and established new technical paradigms for infectious disease prophylaxis. Nonetheless, many next-generation vaccines display suboptimal intrinsic immunogenicity owing to restricted antigenic complexity, resulting in inadequate protective immunity when delivered without adjuvants. Aluminum-containing adjuvants, the most widely deployed clinical adjuvants, primarily potentiate humoral immunity but elicit modest cellular immune responses, thereby failing to satisfy the immunological demands of modern vaccine platforms. Moreover, standard vaccines often fail to confer robust protective immunity in immunocompromised individuals. Accordingly, the rational design and development of next-generation vaccine adjuvants are critical to expanding the clinical translation of innovative vaccines and enhancing immunogenicity in vulnerable populations. In recent years, multiple novel adjuvants have gained clinical approval; of these, Toll-like receptor 4 (TLR4) agonists\u2014core immunostimulatory components of several licensed adjuvant systems\u2014have exhibited potent immunomodulatory activity across diverse infectious disease indications. This review offers a comprehensive synthesis of contemporary TLR4-targeted adjuvants, emphasizing their evolutionary development, molecular mechanisms of action, and clinical translational landscape. We aim to furnish mechanistic insights and translational guidance for scientists optimizing current adjuvants and discovering new TLR4-based candidates.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1872018","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:47Z","timestamp":1784180267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiasheng","family":"Zhou","sequence":"first","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Chen","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Fu","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Du","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhegang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Biological Products Co. Ltd.","place":["Wuhan, China"]},{"name":"National Engineering Technology Research Center for Combined Vaccines","place":["Wuhan, China"]},{"name":"Hubei Provincial Vaccine Technology Innovation Center","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122331","article-title":"Vaccine development: Current trends and technologies","volume":"336","author":"Poria","year":"2024","journal-title":"Life Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043109","article-title":"New-age vaccine adjuvants, their development, and future perspective","volume":"14","author":"Verma","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12497","article-title":"Humoral and cellular responses to a single dose of Fendrix in renal transplant recipients with non\u2010response to previous hepatitis B vaccination","volume":"85","author":"Lindemann","year":"2017","journal-title":"Scand J Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature07830","article-title":"The structural basis of lipopolysaccharide recognition by the TLR4\u2013MD-2 complex","volume":"458","author":"Park","year":"2009","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/287795a0","article-title":"Mutations affecting segment number and polarity in Drosophila","volume":"287","author":"N\u00fcsslein-Volhard","year":"1980","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila Toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.8.4304","article-title":"Toll\/IL-1 receptor domain-containing adaptor inducing IFN-\u03b2 (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-\u03baB and IFN-regulatory factor-3, in the Toll-like receptor signaling","volume":"171","author":"Sato","year":"2003","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/intimm\/dxh186","article-title":"Toll-like receptors in innate immunity","volume":"17","author":"Takeda","year":"2004","journal-title":"Int Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.28","article-title":"TLR2 and TLR4 signaling pathways are required for recombinant Brucella abortus BCSP31-induced cytokine production, functional upregulation of mouse macrophages, and the Th1 immune response in vivo and in vitro","volume":"11","author":"Li","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186188","article-title":"Surface immunogenic protein from Streptococcus agalactiae and Fissurella latimarginata hemocyanin are TLR4 ligands and activate MyD88- and TRIF dependent signaling pathways","volume":"14","author":"D\u00edaz-Dinamarca","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2023.121591","article-title":"Structural analysis of a soluble polysaccharide GSPA-0.3 from the root of Panax ginseng C. A. Meyer and its adjuvant activity with mechanism investigation","volume":"326","author":"Feng","year":"2024","journal-title":"Carbohydr Polym"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41467-020-15030-4","article-title":"Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109622200","article-title":"The Carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes","volume":"277","author":"Iovine","year":"2002","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1201193109","article-title":"Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4\/MD-2","volume":"109","author":"Ohto","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature01180","article-title":"The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors","volume":"420","author":"Horng","year":"2002","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.022392","article-title":"An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4","volume":"284","author":"Motshwene","year":"2009","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.01.019","article-title":"A promiscuous lipid-binding protein diversifies the subcellular sites of Toll-like receptor signal transduction","volume":"156","author":"Bonham","year":"2014","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88\u2013IRAK4\u2013IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Lin","year":"2010","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.6705","article-title":"Cutting edge: Involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production","volume":"178","author":"Chang","year":"2007","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903793","article-title":"Resident and monocyte-derived dendritic cells become dominant IL-12 producers under different conditions and signaling pathways","volume":"185","author":"Zhan","year":"2010","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.01.011","article-title":"Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the anti-viral germinal center response","volume":"34","author":"Hou","year":"2011","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12936-023-04638-8","article-title":"The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals","volume":"22","author":"Tamborrini","year":"2023","journal-title":"Malar J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.plipres.2009.06.002","article-title":"Lipopolysaccharide: Biosynthetic pathway and structure modification","volume":"49","author":"Wang","year":"2010","journal-title":"Prog Lipid Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2003.07.010","article-title":"Structure of bacterial lipopolysaccharides","volume":"338","author":"Caroff","year":"2003","journal-title":"Carbohydr Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.001439","article-title":"Microbial primer: Lipopolysaccharide \u2013 a remarkable component of the Gram-negative bacterial surface: This article is part of the Microbial Primers collection","volume":"170","author":"VanOtterloo","year":"2024","journal-title":"Microbiol (Read)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127413","article-title":"The success of toll-like receptor 4 based vaccine adjuvants","volume":"61","author":"Carter","year":"2025","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13104-022-05941-4","article-title":"Very low concentration of lipopolysaccharide can induce the production of various cytokines and chemokines in human primary monocytes","volume":"15","author":"Chaiwut","year":"2022","journal-title":"BMC Res Notes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1615\/critrevimmunol.v31.i5.20","article-title":"LPS-induced cytokine production in human monocytes and macrophages","volume":"31","author":"Rossol","year":"2011","journal-title":"Crit Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00680","article-title":"Innate immune programing by endotoxin and its pathological consequences","volume":"5","author":"Morris","year":"2015","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(18)33836-5","article-title":"Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium","volume":"257","author":"Qureshi","year":"1982","journal-title":"J Biol Chem"},{"key":"B35","first-page":"99","article-title":"The adjuvant properties of a nontoxic monophosphoryl lipid a in hyporesponsive and aging mice","volume":"6","author":"Tomai","year":"1987","journal-title":"J Biol Response Modif"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0966-842x(02)02426-5","article-title":"Taking toll: Lipid A mimetics as adjuvants and immunomodulators","volume":"10","author":"Persing","year":"2002","journal-title":"Trends Microbiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4","volume":"316","author":"Mata-Haro","year":"2007","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.2.1203","article-title":"A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1\u03b2 or activation of caspase-1","volume":"176","author":"Okemoto","year":"2006","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.8.3239-3247.1997","article-title":"Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages","volume":"65","author":"Salkowski","year":"1997","journal-title":"Infect Immun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.03.008","article-title":"Adjuvants for human vaccines","volume":"24","author":"Alving","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B41","first-page":"1","article-title":"Saponins as vaccine adjuvants","volume":"13","author":"Kensil","year":"1996","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl3381","article-title":"Functional and epigenetic changes in monocytes from adults immunized with an AS01-adjuvanted vaccine","volume":"16","author":"Bechtold","year":"2024","journal-title":"Sci Transl Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241241049","article-title":"Vaccines for respiratory syncytial virus prevention in older adults","volume":"58","author":"Wroblewski","year":"2024","journal-title":"Ann Pharmacother"},{"key":"B48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of respiratory syncytial virus vaccines in older adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.adv5572","article-title":"Precise targeting of HIV broadly neutralizing antibody precursors in humans","volume":"389","author":"Caniels","year":"2025","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00124-9","article-title":"Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial","volume":"12","author":"Dagnew","year":"2025","journal-title":"Lancet HIV"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0079-5","article-title":"Clinical update of the AS04-adjuvanted human papillomavirus-16\/18 cervical cancer vaccine, cervarix\u00ae","volume":"26","author":"Schwarz","year":"2009","journal-title":"Adv Ther"},{"key":"B53","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.081","article-title":"Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial","volume":"31","author":"Abu-Elyazeed","year":"2013","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-11","article-title":"Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S\/AS02(D) malaria vaccine in infants living in a malaria-endemic region","volume":"12","author":"Abdulla","year":"2013","journal-title":"Malar J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0b013e3182373b77","article-title":"Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120\/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals","volume":"59","author":"Lichterfeld","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.03.040","article-title":"Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials","volume":"32","author":"Van Damme","year":"2014","journal-title":"Vaccine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","article-title":"CpG oligonucleotides as vaccine adjuvants","volume":"2197","author":"Kayraklioglu","year":"2021","journal-title":"Methods Mol Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02503-0","article-title":"The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients","volume":"69","author":"Rosenbaum","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in metastatic melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00492-17","article-title":"Rationally designed TLR4 ligands for vaccine adjuvant discovery","volume":"8","author":"Gregg","year":"2017","journal-title":"mBio"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.101","article-title":"A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model","volume":"36","author":"Gregg","year":"2018","journal-title":"Vaccine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41598-023-27965-x","article-title":"Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice","volume":"13","author":"Haupt","year":"2023","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201141855","article-title":"A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo","volume":"42","author":"Pantel","year":"2012","journal-title":"Eur J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.051","article-title":"Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells","volume":"30","author":"Schneider","year":"2012","journal-title":"Vaccine"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aas9930","article-title":"The adjuvant GLA-AF enhances human intradermal vaccine responses","volume":"4","author":"Carter","year":"2018","journal-title":"Sci Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30739-X","article-title":"PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study","volume":"20","author":"Sirima","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1441944","article-title":"Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans","volume":"15","author":"Fiore-Gartland","year":"2024","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"Santini-Oliveira","year":"2016","journal-title":"Vaccine"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.050","article-title":"A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults","volume":"38","author":"Duthie","year":"2020","journal-title":"Vaccine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186927","article-title":"Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns","volume":"135","author":"Violari","year":"2025","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00157-17","article-title":"Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses","volume":"24","author":"Falloon","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00104-X","article-title":"Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial","volume":"24","author":"Zinsou","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206838","article-title":"Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design","volume":"13","author":"Viegas","year":"2018","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.08.075","article-title":"A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area","volume":"37","author":"Keitel","year":"2019","journal-title":"Vaccine"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae062","article-title":"Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with glucopyranosyl lipid A-liposome Quillaja saponaria 21: results of phase 1 testing with malaria challenge","volume":"229","author":"Friedman-Klabanoff","year":"2024","journal-title":"J Infect Dis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"263ra160","DOI":"10.1126\/scitranslmed.3009980","article-title":"Rational design of small molecules as vaccine adjuvants","volume":"6","author":"Wu","year":"2014","journal-title":"Sci Transl Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.63","article-title":"A structure\u2010function approach to optimizing TLR4 ligands for human vaccines","volume":"5","author":"Carter","year":"2016","journal-title":"Clin Trans Imm"},{"key":"B83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41541-022-00467-z","article-title":"An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21","volume":"7","author":"Nam","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1001\/jamaoncol.2023.4015","article-title":"Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma: a phase 1 nonrandomized controlled trial","volume":"9","author":"Seo","year":"2023","journal-title":"JAMA Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0116-6","article-title":"The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine","volume":"4","author":"Liang","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.706157","article-title":"Effect of two unique nanoparticle formulations on the efficacy of a broadly protective vaccine against Pseudomonas aeruginosa","volume":"12","author":"Howlader","year":"2021","journal-title":"Front Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.5.773","article-title":"E6020: a synthetic toll-like receptor 4 agonist as a vaccine adjuvant","volume":"6","author":"Ishizaka","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200495","article-title":"E6020, a TLR4 agonist adjuvant, enhances both antibody titers and isotype switching in response to immunization with hapten-protein antigens and is diminished in mice with TLR4 signaling insufficiency","volume":"209","author":"Gopalakrishnan","year":"2022","journal-title":"J Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41541-024-01046-0","article-title":"SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate","volume":"9","author":"Luna","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011519","article-title":"The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection","volume":"17","author":"Nguyen","year":"2023","journal-title":"PloS NeglTrop Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3750-y","article-title":"A phase I\/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer","volume":"156","author":"Curigliano","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1189","article-title":"Intravesical Bacillus Calmette Guerin combined with a cancer vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients","volume":"23","author":"Derr\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.08.048","article-title":"First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-na\u00efve adults","volume":"40","author":"Hutter","year":"2022","journal-title":"Vaccine"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00410-X","article-title":"SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial","volume":"5","author":"Ober Shepherd","year":"2024","journal-title":"Lancet Microbe"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872018\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:48Z","timestamp":1784180268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872018\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2026.1872018"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1872018","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1872018"}}